You are here

Right or Left? In Colorectal Cancer, Side Matters

Eric Van Cutsem, MD, PhD, Co-Chairman of the 2017 ESMO World Congress on Gastrointestinal Cancer, explains why side matters in colorectal cancer. Left-sided tumors have different and often better outcomes, responding better to some therapies than their right-side counterparts. However, research is zeroing in on treatments to fight right-side tumors more effectively.

2017 ESMO World Congress on Gastrointestinal Cancer

SIRT for Liver Cancer: Similar Efficacy, Less Toxicity Than Sorafenib

Valérie Vilgrain, MD, of Hôpital Beaujon Service de Radiologie in Paris, describes results of the SARAH trial. Selective internal radiation therapy provided efficacy similar to sorafenib for hepatocellular carcinoma but with considerably fewer adverse events.

European Association for the Study of the Liver International Liver Congress, April 2017

ESMO’s New Guidelines for Metastatic Colorectal Cancer

Eric Van Cutsem, MD, Chairperson of the ESMO Consensus Conference, discusses the new ESMO consensus guidelines for the management of metastatic colorectal cancer. Among other things, the detailed document discusses biomarker testing, emerging technologies, and the multidisciplinary, multimodal approaches used increasingly in treatment.

ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016

How a Texas ACO Corralled Diabetes

Jose F. Peña, MD, head of the Rio Grande Valley ACO, describes impressive results for the organization’s comprehensive program to improve diabetes care and lower related Medicare costs in one of the nation’s poorest areas.

American Diabetes Association 76th Scientific Sessions, June 2016

Promising Results for Three Intralesional Oncolytic Agents

Robert H. I. Andtbacka, MD, of the Huntsman Cancer Institute in Utah, reports on three oncolytic immunotherapy studies involving intralesional agents. The combinations of HF10 with ipilimumab and PV-10 with radiation showed promising results, while a study of responders and nonresponders to coxsackievirus A21 suggests avenues for future research.

American Society of Clinical Oncology, June 2016

Pages